Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Go Vida Plena vs Kina

Go Vida Plena
Graded #151

Lower grade

vs+1.8999999999999915
Kina
Graded #107

Higher grade

The verdict

Kina takes it — 70.1/100 to 68.2/100, but only just.

Kina grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Kina is a menopause-care telehealth platform where GLP-1 is the weight-loss treatment, offered alongside HRT, peptide, and compounded options for menopause symptoms. Go Vida Plena is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueKina +7
54
61
Dose & formulationGo Vida Plena +11
75
64
Clinical oversightKina +5
83
88
Labs & monitoringKina +1
63
64
FulfillmentKina +6
77
83
Contract termsKina +6
55
61
Go Vida Plena · left barKina · right bar

The numbers

MetricGo Vida PlenaKina
WeighScore68.2/10070.1/100
GradeCC
Scorecard rank#151#107
Semaglutide$199/mo (starting dose, compounded)$179/mo (starting dose, plus a separate fee, compounded)
Tirzepatide$269/mo (starting dose, compounded)$179/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualYesInjection only
Go Vida Plena

Graded #151 · C

Strengths

  • Spanish-first, fully bilingual GLP-1 program tailored to Latino food and lifestyle - a genuinely underserved niche
  • Compounded semaglutide, tirzepatide, and oral semaglutide from $199/mo, with installment pay (Klarna, Afterpay, Affirm)
  • Free initial consultation; medications shipped discreetly to your door after a medical evaluation
  • Includes 24/7 support, 4 virtual visits a year, and ongoing nutrition coaching
  • Physician-supervised program (Utah medical backing) with continuous follow-up

Where it loses points

  • Utah-based, and the full list of states served is not published
  • Only a '$199/mo starting' price is shown upfront; tirzepatide and oral-semaglutide pricing isn't published
  • The compounding pharmacy is not named (a 'provider pharmacies' page exists but lists no name)
  • Compounded GLP-1 medications are not FDA-approved - not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • No LegitScript certification displayed
Kina

Graded #107 · C

Strengths

  • Menopause-specialized care — GLP-1 weight treatment alongside HRT, peptide, and compounded options for menopause symptoms
  • Prescribed and monitored by named board-certified physicians at Arora Health & Aesthetics, with dose adjustments included
  • Verifiable LegitScript certification (seal ID 50917967)
  • GLP-1 from $179/month with $0 membership fees, FSA/HSA eligibility, free shipping, and cancel-anytime
  • Compounded semaglutide and tirzepatide, 100% online with a roughly 2-minute intake

Where it loses points

  • Compounded medications are not FDA-approved — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • Built for women navigating menopause — less tailored if that is not your situation
  • A separate $50 physician consultation fee applies on top of the medication price
  • The compounding pharmacy partner is not named, and the full list of served states is not published

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard